The goal of SHaRe, a first-of-its-kind effort, is to advance the understanding of Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), and Arrhythmogenic Cardiomyopathy, three types of heritable heart disease affecting nearly 2.4 million adults and children globally.

By building the world’s most robust database of its kind, cardiovascular geneticists and research-based cardiologists will be able to expand their knowledge base and generate fresh insights and research initiatives supporting the development of more targeted and effective approaches in the treatment of genetic heart disease.

Supported through research grants by multinational partners MyoKardia (originally), Bristol Myers Squibb, Pfizer, Cytokinetics, BioMarin, and Tenaya Therapeutics, SHaRe brings together an expert group of experienced and knowledgeable cardiologists and geneticists from the United States, Europe, Australia, and South America with a passion for helping people with genetic heart disease.